Abstract
Introduction:
Extracellular ATP (eATP) released from damaged cells activates the P2X7 receptor (P2X7R) ion channel on the surface of surrounding cells, resulting in calcium influx, potassium efflux and inflammasome activation. Inherited changes in the P2X7R gene (P2RX7) influence eATP induced responses. Single nucleotide polymorphisms (SNPs) of P2RX7 influence both function and signaling of the receptor, that in addition to ion flux includes pathogen control and immunity.
Methods:
Subjects (n = 105) were admitted to the ICU at the University Hospital Ulm, Germany between June 2018 and August 2019. Of these, subjects with a diagnosis of sepsis (n = 75), were also diagnosed with septic shock (n = 24), and/or pneumonia (n = 42). Subjects with pneumonia (n = 43) included those without sepsis (n = 1), sepsis without shock (n = 29) and pneumonia with septic shock (n = 13). Out of the 75 sepsis/septic shock patients, 33 patients were not diagnosed with pneumonia. Controls (n = 30) were recruited to the study from trauma patients and surgical patients without sepsis, septic shock, or pneumonia. SNP frequencies were determined for 16 P2RX7 SNPs known to affect P2X7R function, and association studies were performed between frequencies of these SNPs in sepsis, septic shock, and pneumonia compared to controls.
Results:
The loss-of-function (LOF) SNP rs17525809 (T253C) was found more frequently in patients with septic shock, and non-septic trauma patients when compared to sepsis. The LOF SNP rs2230911 (C1096G) was found to be more frequent in patients with sepsis and septic shock than in non-septic trauma patients. The frequencies of these SNPs were even higher in sepsis and septic patients with pneumonia. The current study also confirmed a previous study by our group that showed a five SNP combination that included the GOF SNPs rs208294 (C489T) and rs2230912 (Q460R) that was designated #21211 was associated with increased odds of survival in severe sepsis.
Discussion:
The results found an association between expression of LOF P2RX7 SNPs and presentation to the ICU with sepsis, and septic shock compared to control ICU patients. Furthermore, frequencies of LOF SNPs were found to be higher in sepsis patients with pneumonia compared to those without pneumonia. In addition, a five SNP GOF combination was associated with increased odds of survival in severe sepsis. These results suggest that P2RX7 is required to control infection in pneumonia and that inheritance of LOF variants increases the risk of sepsis when associated with pneumonia. This study confirms that P2RX7 genotyping in pneumonia may identify patients at risk of developing sepsis. The study also identifies P2X7R as a target in sepsis associated with an excessive immune response in subjects with GOF SNP combinations.
1 Introduction
The clinical course of critically ill patients requiring intensive care involves systemic inflammation to clear pathogens followed by profound immunosuppression to allow healing and recovery. Tissue damage and bacterial or viral infections trigger upregulation and activation of the pattern-recognition receptor (PRR)/danger-associated molecular pattern (DAMP) receptor, P2X7 receptor (P2X7R) which activates the inflammasome and subsequent cytokine release. This characterizes sepsis as a disease with multifactorial debilitating conditions and loss of immune control to nosocomial and community-acquired infections with a high risk of death. The imbalance of the immune response appears to be responsible for the high risk of mortality in patients with sepsis, making it a major problem for intensive care units worldwide.
In 1972, Burnstock introduced the concept of purinergic signaling, describing adenosine triphosphate (ATP) as a major stressor for cells and tissues. In contrast, its metabolite adenosine, generated by cell surface expressed nucleotidases, was found to be a major immunosuppressor (). ATP release occurs due to tissue damage, hypoxia, mechanical stimulation, changes in osmotic pressure (), surgery (), and hemorrhage (). The most severe form of sepsis, septic shock, is associated with failure of the vascular system and metabolic insufficiency, resulting in hypotension and elevated serum lactate (). In addition to its role in inflammation and immune dysfunction, P2X7R has been shown to be an essential receptor for macrophage-mediated bacterial killing (). Furthermore, recent evidence suggests that P2X7R stimulation may modulate the host response by dampening inflammation by stimulating CD14 release from macrophages ().
The controversial molecular evidence for P2X7R influencing tissue damage, inflammation, and immune dysfunction may be related in part to its high numbers of genetic polymorphisms including both loss-of-function (LOF) and gain-of-function (GOF) single nucleotide polymorphisms (SNPs) (). Several studies have investigated the effect of SNP characteristics and their effect on P2X7R ion channel function and pro-inflammatory cytokine release (–). In addition to SNPs, the receptor can be modified by alternative splicing events (–).
P2X7R consists of three P2X7 protein subunits and is found on the membranes of cell surfaces and intracellular organelles (). Inflammatory conditions can differentially modulate the membrane expression of P2X7 and affect eATP signaling in defined phases of sepsis ().
In one of our previous studies, combinations of LOF and GOF SNPs were identified in patients with sepsis and in patients with virus-induced hemophagocytic syndromes which appear to be related to better survival and higher frequencies in patients with hemophagocytic lymphohistiocytosis (HLH) ().
The current genetic association study measured the allele frequencies of LOF and GOF SNPs of the P2X7 gene (P2RX7) in intensive care unit (ICU) patients who were either non-septic or suffered from sepsis, septic shock, with and without pneumonia. It was hypothesized that LOF P2RX7 SNPs might protect against excessive systemic inflammation and sepsis, but at the expense of pathogen clearance, whereas GOF P2RX7 SNPs might be linked to better pathogen control, but increased risk of sepsis.
2 Materials and methods
2.1 Study population
This study was approved by the Ethics Committee of Ulm University (application no. 284/18). Subjects (n = 105) for the study were recruited from the anesthesiologic ICU at the University Hospital Ulm, Germany between June 2018 and August 2019 (see Figure 1). Subjects were aged between 18 and 84 years and there were 77 males and 28 females. The mean age of the patients was 61.06 years (SD 15.82 years). Clinical information for each patient included is given in Supplementary Table 1, including information on co-morbidities, sterile trauma/hemorrhage, obesity, diabetes type 2, malignancies, chronic obstructive pulmonary disease (COPD), asthma, alcohol or nicotine abuse, organ dysfunction syndromes, as well as infections before manifesting critical illness. Thirty patients were non-septic, 75 patients were diagnosed with sepsis, of which 24 patients were in septic shock (Figure 1). Forty-two patients had pneumonia and sepsis including 13 patients with septic shock. Out of the 75 sepsis/septic shock patients, 33 patients did not suffer from pneumonia (Figure 1).
Figure 1
Non-septic patients comprised two major groups: i) patients with polytrauma (n=9) and ii) patients with major surgical interventions (n=25) including tumor resection (n=2), surgery related to a vascular disease (n=9) or neurosurgery (n=6). A total of n=6 patients from the polytrauma group underwent surgery during their stay in the ICU. The remaining three patients underwent surgery for hemorrhagic shock, compartment syndrome, and atypical gastric resection due to obesity. There were only two patients who did not belong to one of the two main groups: One patient was monitored in the ICU for Stanford type B aortic dissection, and the other patient had a bowel obstruction that did not require surgery (see Supplementary Table 1 for more details).
2.2 Study design, DNA isolation, and genotyping
Following the patients’ characteristics given in Figure 1, a total of 105 patients were studied. The first step was to determine how many patients had sepsis (n=75) and how many did not have sepsis (n=30). Using these two groups, we investigated whether there were statistical differences with regard to the genetics of P2RX7. Subsequently, we studied for differences in P2RX7 SNP frequencies in patients with septic shock (n=24) and patients without septic shock (n=81). Finally, this study calculated P2RX7 SNP frequencies for all patients with pneumonia (n=43) versus patients without pneumonia (n=62) Figure 1.
Semi-automated DNA purification was done by using a Maxwell 16® LEV Blood DNA Kit and a Maxwell 16® (#AS1290, Promega®) (https://www.promega.com) instrument. A total of 300 µl of fresh EDTA blood from each patient (pseudonymized by a KeyPat-Id number), was mixed with 300 µl of Promega lysis buffer plus 30 µl Proteinase K (supplied in the kit). The samples were then vortexed for 10 seconds and incubated at 56°C for 20 min using a water bath. The high temperature and the detergents guanidinium thiocyanate (50-75%) and polyethylene glycol tert-octyl-phenyl ether (Triton-X, < 2%), which are components of the lysis buffer, lead to lysis of cell and nuclear membranes. The proteinase K degrades various proteins. Histones are also degraded, enabling the release of genomic DNA (gDNA). After the incubation time, the lysed blood sample was pipetted into well No.1 of the Maxwell 16® cartridge. The cartridges were placed into the cartridge holder with a plunger and an additional tube, containing 60 µl elution buffer. The cartridge holder was then placed inside the Maxwell 16® Instrument and the machine was started. The Maxwell 16® instrument uses paramagnetic particles, the MagnaCel™ particle, which takes advantage of the cellulose binding capacity of nucleic acids. During the automated purification process, gDNA is bound to the paramagnetic particle, washed with ethanol and eventually released into the elution buffer. Absorbance measurements determined the grade of genomic deoxyribonucleic acid (gDNA) using the NanoDrop® 1000 version 3.8.1 (https://www.thermofisher.com). After DNA isolation, 16 P2RX7 SNPs (Table 1, Figures 2, 3A) were genotyped using MassARRAY® technology following the manufacturers advice from Agena Bioscience (https://www.agenabio.com).
Table 1
| dbSNP ID | amino acid change | position | function |
|---|---|---|---|
| rs2393799 (C-762T) | – | promotor | Decreased receptor expression () |
| rs35933842 (G151 + 1T) | - | intron 1 | Splice site mutation, P2X7 null allele () |
| rs17525809 (T253C) | Val-76>Ala | exon 2 | Partial LOF (, ) |
| rs28360447 (G474A) | Gly-150>Arg | exon 5 | LOF () |
| rs208294 (C489T) | His-155>Tyr | exon 5 | GOF () |
| rs208307 (C641-5G) | - | intron 6 | Promotes exon 7, 8 skipping, null function () |
| rs7958311 (G835A) | His-270>Arg | exon 8 | Remains unclear [LOF (), GOF ()] |
| rs7958316 (G853A) | Arg-276>His | exon 8 | LOF () |
| rs28360457 (G946A) | Arg-307>Gln | exon 9 | LOF () |
| rs1718119 (G1068A) | Ala-348>Thr | exon 11 | GOF () |
| rs2230911 (C1096G) | Thr-357>Ser | exon 11 | LOF () |
| rs2230912 (A1405G) | Gln-460>Arg | exon 13 | Remains unclear [LOF (), GOF ()] |
| rs3751143 (A1513C) | Glu-496>Ala | exon 13 | LOF (, ) |
| rs3751142 (G1628T) | Leu534Leu | exon 13 | Synonymous variant () |
| rs1653624 (T1729A) | Ile-568>Asn | exon 13 | LOF (, ) |
| rs1621388 (G1772A) | Pro582Pro | exon 13 | Synonymous variant (, ) |
Visualization of the investigated SNPs with location in the gene/protein, the change in the amino acid chain and the impact on receptor function.
Figure 2
2.3 Statistical analysis
IBM SPSS® version 26 was used for statistical data analysis with an α<0.05 level of significance used for all calculations. Patient characteristics such as age, sex, or length of stay were first tested for normal distribution using the Kolmogorov-Smirnov and Shapiro-Wilk tests. Because the data were not normally distributed, differences between mean tendencies were calculated using the Mann-Whitney U test. Odds ratios (OR) and 95% confidence intervals (CI) were reported for significant results.
All P2RX7 SNPs (n=16) were first tested for deviations from Hardy Weinberg Equilibrium (HWE). Next, linkage disequilibrium (LD) was determined for all SNPs using Haploview version 4.2 and analyzed according to the Broad Institute’s standard coloring scheme (
Table 2
| GLOBAL | EUROPE | COHORT n=105 | |
|---|---|---|---|
| rs2393799 (C-762T) | C=0.75697 T=0.24303 | C=0.82278 T=0.17722 | C=0.75238 T=0.24761 |
| rs35933842 (G151 + 1T) | G=0.99243 T=0.00757 | G=0.99177 T=0.00823 | G=0.99523 T=0.00476 |
| rs17525809 (T253C) | T=0.93101 C=0.06899 | T=0.92747 C=0.07253 | T=0.91428 C=0.08571 |
| rs28360447 (G474A) | G=0.98412 A=0.01588 | G=0.98279 A=0.01721 | G=0.98571 A=0.01428 |
| rs208294 (C489T) | C=0.54850 T=0.45150 | C=0.55220 T=0.44780 | C=0.52884 T=0.47115 |
| rs208307 (C641-5G) | C=0.70101 G=0.29899 | C=0.69956 G=0.30044 | C=0.68571 G=0.31428 |
| rs7958311 (G835A) | G=0.74385 A=0.25615 | G=0.74711 A=0.25289 | G=0.75714 A=0.24285 |
| rs7958316 (G853A) | G=0.98106 A=0.01894 | G=0.97922 A=0.02078 | G=0.98571 A=0.01428 |
| rs28360457 (G946A) | G=0.98759 A=0.01241 | G=0.98652 A=0.01348 | G=0.99047 A=0.00952 |
| rs1718119 (G1068A) | G=0.61770 A=0.38230 | G=0.60919 A=0.39081 | G=0.65048 A=0.34951 |
| rs2230911 (C1096G) | C=0.91342 G=0.08659 | C=0.9236 G=0.0764 | C=0.92380 G=0.07619 |
| rs2230912 (A1405G) | A=0.84448 G=0.15553 | A=0.83368 G=0.16632 | A=0.84761 G=0.15238 |
| rs3751143 (A1513C) | A=0.81091 C=0.18909 | A=0.81076 C=0.18924 | A=0.77142 C=0.22857 |
| rs3751142 (G1628T) | G=0.90755 T=0.09245 | G=0.92216 T=0.07784 | G=0.92380 T=0.07619 |
| rs1653624 (T1729A) | T=0.98173 A=0.01827 | T=0.97967 A=0.02033 | T=0.98058 A=0.01941 |
| rs1621388 (G1772A) | G=0.62878 A=0.37122 | G=0.61737 A=0.38263 | G=0.63809 A=0.36190 |
Comparison of MAFs of SNPs in our cohort with published MAFs from the ALFA project (MAF dbSNP accessed 4/1/2024 https://www.ncbi.nlm.nih.gov/snp/ALFAAlleleFrequency).
In addition to the analysis of individual SNPs, a combination of five SNPs (rs208294 (C489T), rs28360457 (G946A), rs2230912 (A1405G), rs3751143 (A1513C), and rs1653624 (T1729A)) (
3 Results
3.1 Analysis of the study population
Patients with pneumonia and sepsis had significantly prolonged hospital and ICU stays compared to all patients. On average, patients spent 46.6 days in the hospital and 20.3 days in the ICU. Patients with pneumonia spent on average 55.1 days in the hospital (p=0.006) and 25.9 days in the ICU (p=0.001). Patients with sepsis spent on average 53.2 days in hospital (p=0.005) and 24.3 days in ICU (p<0.001). In contrast, septic shock patients had shorter hospital and ICU stays than the overall study population (38.5 vs. 18.7 days, respectively). Septic shock patients were older than other patients (mean age 65.92 vs. 61.06 years, respectively) and were more likely to die [45.8% vs. 27.6%, respectively, p=0.023; OR: 2.96 (1.14-7.73)]. In the entire cohort, 29 patients (27.6%) died, of which 18 patients were male (62.1%) and 11 patients were female (37.9%).
3.2 Calculation of the Hardy-Weinberg equilibrium and linkage disequilibrium
All 16 SNPs were first tested for deviation from HWE, with only two SNPs [rs2230911 (C1096G) and rs3751142 (G1628T)] deviating from HWE (Table 3). The SNPs rs35933842 (G151 + 1T) and rs28360457 (G946A) were excluded from further analysis because of a MAF <1% (Table 3). Most of the calculated allele frequencies were consistent with the globally published frequencies from the ALFA project (
Table 3
| dbSNP ID | HWE | MAF | |
|---|---|---|---|
| Chi2-test | p-value | ||
| rs2393799 (C-762T) | 1.801 | 0.180 | 0.248 |
| rs35933842 (G151 + 1T) | 0.002 | 0.961 | 0.005* |
| rs17525809 (T253C) | 0.923 | 0.337 | 0.086 |
| rs28360447 (G474A) | 0.022 | 0.882 | 0.014 |
| rs208294 (C489T) | 0.183 | 0.669 | 0.471 |
| rs208307 (C641-5G) | 0.544 | 0.461 | 0.314 |
| rs7958311 (G835A) | 0.010 | 0.918 | 0.243 |
| rs7958316 (G853A) | 0.022 | 0.882 | 0.014 |
| rs28360457 (G946A) | 0.010 | 0.922 | 0.010* |
| rs1718119 (G1068A) | 0.377 | 0.539 | 0.350 |
| rs2230911 (C1096G) | 10.985* | 0.001* | 0.076 |
| rs2230912 (A1405G) | 0.180 | 0.671 | 0.152 |
| rs3751143 (A1513C) | 1.936 | 0.164 | 0.229 |
| rs3751142 (G1628T) | 10.985* | 0.001* | 0.076 |
| rs1653624 (T1729A) | 0.040 | 0.841 | 0.019 |
| rs1621388 (G1772A) | 0.902 | 0.342 | 0.362 |
Hardy-Weinberg-equilibrium (HWE) and Minor Allele Frequencies (MAFs) of the investigated SNPs.
SNPs deviating from HWE or with an MAF <1% are highlighted in bold letter with *.
Figure 3

(A) LD Plot of P2RX7. The display was performed according to the Broad Institute’s Standard Color Scheme. The number in the boxes refers to the coefficient D’. SNPs that showed associations with pneumonia and/or sepsis are in red. (B) Structure of the P2RX7 gene with the location of studied SNPs. SNPs with statistically significant results in the current study are highlighted red, SNPs being part of the SNP combination model are highlighted in grey boxes. (C) Illustration of two important SNP combinations related to survival, filled symbols indicate heterozygosity and open symbols indicate wildtype genotypes of the respective SNP. (D) Distribution of patients with sepsis with and without pneumonia, who survived/died and their corresponding P2RX7 SNP combinations as defined in a previous study (
3.3 Association of SNPs with clinical endpoints
Four SNPs showed statistically significant associations with the clinical outcomes of pneumonia and/or sepsis, but no association with septic shock or death (Table 4). Two of them were characterized as LOF [rs17525809 (T253C), and rs2230911 (C1096G)], and rs3751142 (G1628T) and rs1621388 (G1772A) are synonymous SNPs with as yet unknown effect on P2X7R function. These results suggest that genetics related to impaired P2X7R function and signaling may play a role in pneumonia and sepsis.
Table 4
| (A) Demonstration of associations between genetic variants with pneumonia | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SNP | Total | Genotype frequency | Model 1 | Model 2 | |||||||
| WT | HET | HOM | p-value | OR | 95% CI | MAF | p-value | OR | 95% CI | ||
| rs17525809 (T253C) | |||||||||||
| Pneumonia | 43 | 40 | 3 | - | 0.021 | 0.24 | (0.06 - 0.87) | 0.035 | 0.028 | 0.26 | (0.07 - 0.94) |
| Non-pneumonia | 62 | 47 | 15 | - | 0.121 | ||||||
| rs2230911 (C1096G) | |||||||||||
| Pneumonia | 43 | 33 | 8 | 2 | 0.012 | 7.15 | (1.43 - 35.67) | 0.140 | 0.004 | 4.85 | (1.51 - 15.63) |
| Non-pneumonia | 62 | 59 | 2 | 1 | 0.032 | ||||||
| rs3751142 (G1628T) | |||||||||||
| Pneumonia | 43 | 33 | 8 | 2 | 0.012 | 7.15 | (1.43 - 35.67) | 0.140 | 0.004 | 4.85 | (1.51 - 15.63) |
| Non-pneumonia | 62 | 59 | 2 | 1 | 0.032 | ||||||
| rs1621388 (G1772A) | |||||||||||
| Pneumonia | 43 | 21 | 18 | 4 | 0.318 | 0.302 | 0.135 | 0.64 | (0.36 - 1.15) | ||
| Non-pneumonia | 62 | 24 | 26 | 12 | 0.403 | ||||||
| (B) Demonstration of associations between genetic variants with sepsis | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SNP | Total | Genotype frequency | Model 1 | Model 2 | |||||||
| WT | HET | HOM | p-value | OR | 95% CI | MAF | p-value | OR | 95% CI | ||
| rs17525809 (T253C) | |||||||||||
| Sepsis | 75 | 68 | 7 | 0.001 | 0.18 | (0.06 - 0.52) | 0.047 | 0.001 | 0.22 | (0.08 - 0.59) | |
| Non-sepsis | 30 | 19 | 11 | 0.183 | |||||||
| rs2230911 (C1096G) | |||||||||||
| Sepsis | 75 | 62 | 10 | 3 | 0.045 | 0.107 | 0.007 | ||||
| Non-sepsis | 30 | 30 | 0.000 | ||||||||
| rs3751142 (G1628T) | |||||||||||
| Sepsis | 75 | 62 | 10 | 3 | 0.045 | 0.107 | 0.007 | ||||
| Non-sepsis | 30 | 30 | 0.000 | ||||||||
| rs1621388 (G1772A) | |||||||||||
| Sepsis | 75 | 36 | 31 | 8 | 0.078 | 0.313 | 0.021 | 0.49 | (0.26 - 0.90) | ||
| Non-sepsis | 30 | 9 | 13 | 8 | 0.483 | ||||||
Presentation of the significant associations between SNPs and clinical endpoints.
The minor variant of rs17525809 (T253C) was linked to reduced risk of developing pneumonia [Model 1: p=0.021, OR HET/WT: 0.24 (0.06 – 0.87), Model 2: MAF cohort with pneumonia 0.035 vs. MAF cohort without pneumonia 0.121, p=0.028, OR minor/major 0.26 (0.07 – 0.94)] and sepsis [Model 1: p=0.001, OR HET/WT: 0.18 (0.06 – 0.52), Model 2: MAF cohort with sepsis 0.047 vs. MAF cohort without sepsis 0.183, p=0.001, OR minor/major: 0.22 (0.08 – 0.59)]. However, as shown in Supplementary Figure 1, a closer look at the data reveals that the heterozygous genotype of the LOF SNP rs17525809 (T253C) is more frequent in sepsis patients with pneumonia than in sepsis patients without pneumonia (6/29 vs 3/22, respectively). An imbalance in rs17525809 (T253C) genotype frequency was also observed when comparing septic and non septic patients.
The minor variant of the LOF SNP rs2230911 (C1096G) was associated with a higher risk of developing pneumonia [Model 1: p=0.012, OR HET/WT: 7.15 (1.43 - 35.67), Model 2: MAF cohort with pneumonia 0.140 vs. MAF cohort without pneumonia 0.032, p=0.004, OR minor/major 4.85 (1.51 - 15.63)] and sepsis [Model 1: p=0.045, OR HET/WT: -, Model 2: MAF cohort with sepsis 0.107 vs. MAF cohort without sepsis 0.000, p=0.007, OR minor/major: -]. Furthermore, the cohort of patients with sepsis or septic shock plus pneumonia had the highest proportion of heterozygous and homozygous mutant genotypes of this SNP (see Supplementary Figure 2).
Subsequent LD calculation with D’=1 showed that the LOF SNP rs2230911 (C1096G) and the synonymous SNP rs3751142 (G1628T) were in strong linkage Figure 3D. In the current cohort of patients analyzed, every patient with a mutation in the LOF SNP rs2230911 (C1096G) was also mutated for rs3751142 (G1628T). As our study is still ongoing, n=250 patients have now been sequenced, of which only two patients were found to differ in the aforementioned combination of SNPs (data not shown).
The present study also found an association between the major variant G of rs1621388 (G1772A) and a higher prevalence of sepsis cases in Model 2 [Model 1: p=0.078, Model 2: MAF cohort with sepsis 0.313 vs. MAF cohort without sepsis 0.483, p=0.021, OR minor/major 0.49 (0.26-0.90)]. The association with rs1621388 (G1772A) was not statistically significant after Bonferroni correction in Model 1. As shown in Supplementary Figure 3, the distribution of wild-type, heterozygous and homozygous mutant variants in our group of non-septic patients is almost equal between wild-type, heterozygous and homozygous mutant genotypes. Sepsis and septic shock patients had lower frequencies of the minor variant. There is no systematic change in these SNP variations when including cases with and without pneumonia. Interestingly, this SNP was in complete LD with the GOF SNP rs1718119 (G1068A) (Figure 3A).
3.4 SNP combinations
In addition to analyzing individual SNPs, this study also investigated associations with previously identified genotype combinations consisting of five P2RX7 SNPs (Figure 3B). Analysis revealed trends between three combinations and clinical outcomes that were just above the threshold for statistical significance. #11111 and #21111 showed adverse effects for ICU patients: #11111 (n=18) was associated with higher mortality [p=0.085, OR 2.60 (0.90 - 7.48)] and #21111 (n=14) with more frequent development of pneumonia [p=0.054, OR 3.06 (0.94 - 9.89)]. In contrast, #21211 (heterozygous at rs208294 His-155>Tyr, rs22309122 Gln-460>Arg, and WT at three other SNPs) (n=14) increased the likelihood of patient survival [p=0.105, OR 0.18 (0.02 - 1.42)]. For clarity, the distribution of #11111, #21121, (heterozygous at rs208294 His-155>Tyr, and rs3751146 Glu-496>Ala, and WT at three other SNPs), #21211 and others among patient groups is shown in Figure 3C. 5/10 patients with #11111 without pneumonia survived, and 5/8 with pneumonia survived. In patients with #21121 and low ion channel function (
4 Discussion
4.1 Clinical aspects of the sample
Several aspects of the collected clinical data and sample distribution suggest that this cohort is a representative study population. The analysis confirmed longer hospitalization and ICU stays for pneumonia and sepsis, but not for septic shock (
4.2 LD block
This present study revealed an LD block between seven SNPs comprising a base length of one kb. The full length of P2RX7 is 53 kb (
Remarkably, mutations in the GOF SNP rs1718119 (G1068A) and the synonymous SNP rs1621388 (G1772A) were identical in all patients presenting with a heterozygous or homozygous mutated genotype but differed in other SNPs. The same was observed for the LOF SNP, rs2230911 (C1096G) and synonymous SNP, rs3751142 (G1628T), but no homozygous mutant genotypes were identified in these two SNPs.
This strong LD between the aforementioned GOF and LOF SNPs on the one hand as well as the combined presence of minor variants of GOF and LOF SNPs in a defined individual is likely linked to the biological function of this receptor since other SNPs in this LD block are not identically mutated in a number of other patients.
4.3 rs17525809 (T253C)
The SNP rs17525809 (T253C) is located in exon 2, which encodes a part of the extracellular loop of P2X7R. The minor variant causes an exchange of valine to alanine at position 76 of the protein (
In the current cohort, the minor variant of this SNP was identified as a heterozygous and not as a homozygous mutation. Similarly, previous publications have reported that a homozygous rs17525809 (T253C) variant is rare (
In previously published studies, the effect of rs17525809 (T253C) varies depending on the investigated pathology. In chronic inflammatory diseases such as gout or MS, the LOF variant was protective (
4.4 rs2230911 (C1096G)
The second SNP with a significant association was rs2230911 (C1096G), which causes an amino acid exchange from threonine to serine at position 357 (
In addition to the above-described location in the CRAC motif, rs2230911 (C1096G) is part of a threonine-serine cluster (357 TYSS 360) which has been postulated to be a potential binding motif for β-arrestin-2. This binding would lead to the internalization of the receptor which is equivalent to its degradation and inactivation (
Previously published reports showed a detrimental effect of the SNP in the context of various pathologies and patients carrying rs2230911 (C1096G) may be prone to develop severe infections due to predisposing comorbidities. The minor allele of rs2230911 (C1096G) was linked to several comorbidities including gout, hyperglycemia with an additional risk of progression to diabetes mellitus or metabolic syndrome (
4.5 rs3751142 (G1628T)
In this study, two synonymous SNPs showed statistically significant results for the clinical endpoints pneumonia and/or sepsis. Although the MAF of the whole cohort was consistent with published allele frequencies (Table 2), patients who were septic or had pneumonia had significantly higher MAF than the respective control cohorts (Table 4). This could be a consequence of LD with functionally relevant non-synonymous SNPs. In this cohort rs3751142 (G1628T) is in complete LD with the non-synonymous LOF SNP rs2230911 (C1096G). Although synonymous SNPs do not lead to amino acid substitutions, changes in the nucleotide sequence of messenger ribonucleic acid (mRNA) can alter protein expression levels, protein isoform expression or protein folding (
The rs3751142 (G1628T) SNP is in exon 13 at an exonic splice enhancer site and may cause exon skipping or decrease mRNA stability leading to nonsense-mediated mRNA decay (
As a relevant observation of P2X7R in sepsis, a recent study addressed the function of P2X7R in patients with early versus late sepsis, and convincingly demonstrated that P2X7R expression is upregulated in the early phase of sepsis. In contrast, in the later phases of sepsis, the P2X7R is released from the membrane and potent immunosuppressive signaling driven by the ATP degradation product adenosine is more prevalent (
4.6 rs1621388 (G1772A)
The major variant G of rs1621388 (G1772A) had a higher prevalence in sepsis cases in Model 2. The SNP rs1621388 (G1772A) is a synonymous SNP, that is in LD with the GOF SNP rs1718119 (G1068A). The rs1621388 (G1772A) SNP is located at an exonic splice enhancer site but is also part of the codon for proline 582 located in an LPS binding domain in the C-terminus of P2X7R (
Future studies should address the selective contribution of gram-negative versus gram-positive bacteria for the development of sepsis in SNP rs1621388 (G1772A) genotypes, especially since this SNP is in LD with the GOF SNP rs1718119 (G1068A).
rs1718119 (G1068A) has previously been shown to increase inflammasome activation through P2X7R activation (
4.7 Previously identified P2RX7 genotypes
Combination SNP analysis in the current study did not reveal a statistically significant result. However, several trends emerged: Firstly, patients with #11111 were 2.6 times more likely to die [p=0.085, OR 2.60 (0.90 - 7.48)]. This SNP combination consists of five wild-type SNPs indicating a highly functional P2X7R. This is linked to high sensitivity to its ligand ATP, pore formation, induction of apoptosis and regulation of phagocytosis (
These results correspond to the highest ion flux linked to genotype #21211, which includes a heterozygous mutation of the GOF SNP rs208294 (C489T), and the partial LOF SNP rs2230912 (A1405G) (
In addition to trauma and sepsis, chemotherapy of tumors is linked to massive ATP release and P2X7R activation. A recent validation study on functional SNPs and outcome after chemotherapy in colorectal carcinoma showed that the P2RX7 GOF SNP rs208294 (C489T) was associated with worse overall survival (OS) and progression free survival, however the P2RX7 LOF SNP rs2230911 (C1096G) was prognostic and predictive, showing improved OS in patients who received oxaliplatin (
4.8 Conclusion
In conclusion, this study provides evidence for the functional relevance of P2X7R to combat sepsis and pneumonia, a severe combination of acquired immune deficiency and life threatening infection. A functionally reduced P2RX7 variant has been identified by the presence of LOF SNPs. Whereas LOF SNPs may be protective against the detrimental effects of hypercytokinemia and excessive systemic inflammation, including neuroinflammation (
4.9 Limitations of the study
The study results are to be interpreted in the context of several limitations, which were mostly of a structural type. Above all, the sample size of n = 105 patients limited the creation of subgroups described by more detailed clinical information. Additionally, the clinical data did not sufficiently include the pre-existing diseases and conditions of the patients despite the critical roles such pre-morbidities play in clinical outcomes (
Despite the above-described limitations, this study provides some evidence on the extent to which genetic variants have a protective or detrimental effect in critically ill patients.
Statements
Author’s note
According to recent findings: Zorina-Lichtenwalter, K., A. R. Ase, V. Verma, A. I. M. Parra, S. Komarova, A. Khadra, P. Séguéla and L. Diatchenko (2024). "Characterization of Common Genetic Variants in P2RX7 and Their Contribution to Chronic Pain Conditions." The Journal of Pain 25(2): 545-556. P2RX7 GOF and LOF functions and genotypes should be distinguished by their effects on channel opening and pore formation which may require functional assays of SNP-genotyped patients‘ derived cells and tissues.
Data availability statement
The original contributions presented in the study are publicly available. This data can be found here: https://oparu.uni-ulm.de/items/12deb668-2371-41f6-b77a-115d8af31887.
Ethics statement
The studies involving humans were approved by Ulm University, Ethics committee. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants’ legal guardians/next of kin.
Author contributions
JG: Investigation, Writing – original draft. SF: Conceptualization, Funding acquisition, Investigation, Writing – original draft. KS: Methodology, Investigation, Writing – review & editing. BM: Methodology, Writing – review & editing, Project administration. ES: Conceptualization, Methodology, Project administration, Supervision, Writing – original draft.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Genotyping of the current cohort was supported by Nepean Medical Research Foundation Project Grant (2018), entitled: P2X7 genotype and haplotype association study in sepsis and severe influenza. This research was also funded by European Union’s Horizon 2020 research VirA (under grant agreement no. 952376, www.vira-twinning.eu).
Acknowledgments
We thank colleagues from the Clinic of Anesthesiology and Intensive Care at Ulm University Hospital for their contribution in study patients’ recruitment. Preliminary results are available in a thesis entitled “Polymorphismen des purinergen Rezeptors P2X7 bei Patienten mit Pneumonie, Sepsis und septischem Schock” and available at https://oparu.uni-ulm.de/xmlui/bitstream/handle/123456789/51076/Diss_Guggemos.pdf?sequence=3&isAllowed=y.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2024.1352789/full#supplementary-material
References
1
BurnstockG. P2X ion channel receptors and inflammation. Purinergic Signal. (2016) 12:59–67. doi: 10.1007/s11302-015-9493-0
2
GallucciSMatzingerP. Danger signals: SOS to the immune system. Curr Opin Immunol. (2001) 13:114–9. doi: 10.1016/S0952-7915(00)00191-6.
3
KomalavilasPLuoWGuthCMJolayemiOBartelsonRICheung-FlynnJet al. Vascular surgical stretch injury leads to activation of P2X7 receptors and impaired endothelial function. PloS One. (2017) 12:e0188069. doi: 10.1371/journal.pone.0188069.
4
ZhaoHChenYFengH. P2X7 receptor-associated programmed cell death in the pathophysiology of hemorrhagic stroke. Curr Neuropharmacology. (2018) 16:1282–95. doi: 10.2174/1570159X16666180516094500.
5
SingerMDeutschmanCSSeymourCWShankar-HariMAnnaneDBauerMet al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. (2016) 315:801–10. doi: 10.1001/jama.2016.0287
6
CsókaBNémethZHTörőGIdzkoMZechAKoscsóBet al. Extracellular ATP protects against sepsis through macrophage P2X7 purinergic receptors by enhancing intracellular bacterial killing. FASEB J. (2015) 29:3626–37. doi: 10.1096/fj.15-272450
7
Alarcón-VilaCBaroja-MazoAde Torre-MinguelaCMartínezCMMartínez-GarcíaJJMartínez-BanaclochaHet al. CD14 release induced by P2X7 receptor restricts inflammation and increases survival during sepsis. Elife. (2020) 9:e60849. doi: 10.7554/eLife.60849.
8
FullerSJStokesLSkarrattKKGuBJWileyJS. Genetics of the P2X7 receptor and human disease. Purinergic Signal. (2009) 5:257–62. doi: 10.1007/s11302-009-9136-4
9
GuBJZhangWWorthingtonRASluyterRDao-UngPPetrouSet al. A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. J Biol Chem. (2001) 276:11135–42. doi: 10.1074/jbc.M010353200.
10
SmartMLGuBPanchalRGWileyJCromerBWilliamsDAet al. P2X7 receptor cell surface expression and cytolytic pore formation are regulated by a distal C-terminal region. J Biol Chem. (2003) 278:8853–60. doi: 10.1074/jbc.M211094200
11
StokesLFullerSJSluyterRSkarrattKKGuBJWileyJS. Two haplotypes of the P2X7 receptor containing the Ala-348 to Thr polymorphism exhibit a gain-of-function effect and enhanced interleukin-1β secretion. FASEB J. (2010) 24:2916–27. doi: 10.1096/fj.09-150862
12
Di VirgilioFDal BenDSartiACGiulianiALFalzoniS. The P2X7 receptor in infection and inflammation. Immunity. (2017) 47:15–31. doi: 10.1016/j.immuni.2017.06.020
13
SkarrattKKGuBJLovelaceMDMilliganCJStokesLGloverRet al. A P2RX7 single nucleotide polymorphism haplotype promotes exon 7 and 8 skipping and disrupts receptor function. FASEB J. (2020) 34:3884–901. doi: 10.1096/fj.201901198RR
14
SkarrattKKFullerSJSluyterRDao-UngLGuBJWileyJS. A 5′ intronic splice site polymorphism leads to a null allele of the P2X7 gene in 1–2% of the Caucasian population. FEBS Lett. (2005) 579:2675–8. doi: 10.1016/j.febslet.2005.03.091
15
NorthRA. Molecular physiology of P2X receptors. Physiol Rev. (2002) 82:1013–67. doi: 10.1152/physrev.00015.2002.
16
Martínez-BanaclochaHGarcía-PalencianoCMartínez-AlarcónLAmores-IniestaJMartín-SánchezFErcoleGAet al. Purinergic P2X7 receptor expression increases in leukocytes from intra-abdominal septic patients. Front Immunol. (2023) 14. doi: 10.3389/fimmu.2023.1297249.
17
GeistlingerJDuWGrollJLiuFHoegelJFoehrKJet al. P2RX7 genotype association in severe sepsis identified by a novel Multi-Individual Array for rapid screening and replication of risk SNPs. Clin Chim Acta. (2012) 413:39–47. doi: 10.1016/j.cca.2011.05.023
18
TaheriMSaraniHMoazeni-RoodiANaderiMHashemiM. Association between P2X7 polymorphisms and susceptibility to tuberculosis: an updated meta-analysis of case-control studies. Medicina. (2019) 55:298. doi: 10.3390/medicina55060298.
19
RogerSMeiZ-ZBaldwinJMDongLBradleyHBaldwinSAet al. Single nucleotide polymorphisms that were identified in affective mood disorders affect ATP-activated P2X7 receptor functions. J Psychiatr Res. (2010) 44:347–55. doi: 10.1016/j.jpsychires.2009.10.005
20
CabriniGFalzoniSForchapSLPellegattiPBalboniAAgostiniPet al. A His-155 to Tyr polymorphism confers gain-of-function to the human P2X7 receptor of human leukemic lymphocytes. J Immunol. (2005) 175:82–9. doi: 10.4049/jimmunol.175.1.82.
21
ShemonANSluyterRFernandoSLClarkeALDao-UngL-PSkarrattKKet al. A thr357 to ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and impairs ATP-induced mycobacterial killing by macrophages. J Biol Chem. (2006) 281:2079–86. doi: 10.1074/jbc.M507816200
22
GuBJSluyterRSkarrattKKShemonANDao-UngLFullerSJet al. An Arg307 to Gln polymorphism within the ATP-binding site causes loss of function of the human P2X7 receptor. J Biol Chem. (2004) 279:31287–95. doi: 10.1074/jbc.M313902200.
23
DenlingerLCCoursinDBSchellKAngeliniGGreenDNGuadarramaAGet al. Human P2X7 pore function predicts allele linkage disequilibrium. Clin Chem. (2006) 52:995–1004. doi: 10.1373/clinchem.2005.065425
24
GadeockSPupovacASluyterVSpildrejordeMSluyterR. P2X7 receptor activation mediates organic cation uptake into human myeloid leukaemic KG-1 cells. Purinergic Signal. (2012) 8:669–76. doi: 10.1007/s11302-012-9320-9.
25
WileyJSDao-UngLLiCShemonANGuBJSmartMLet al. An Ile-568 to Asn polymorphism prevents normal trafficking and function of the human P2X7 receptor. J Biol Chem. (2003) 278:17108–13. doi: 10.1074/jbc.M212759200.
26
KoppRKrautloherARamírez-FernándezANickeA. P2X7 interactions and signaling - making head or tail of it. Front Mol Neurosci. (2019) 12:183. doi: 10.3389/fnmol.2019.00183
27
Broad institute. LD Display. (2022) 2022):.
28
LaurieCCDohenyKFMirelDBPughEWBierutLJBhangaleTet al. Quality control and quality assurance in genotypic data for genome-wide association studies. Genet Epidemiol. (2010) 34:591–602. doi: 10.1002/gepi.20516
29
PhanLJinYZhangHQuianaWShektmanEShawDet al. ALFA: allele frequency aggregator. National center for biotechnology information, U.S. Natl Library Med. (2020) 2022.
30
VincentJ-LRelloJMarshallJSilvaEAnzuetoAMartinCDet al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. (2009) 302:2323–9. doi: 10.1001/jama.2009.1754
31
NingDGargKMayerBSchickBBrachtHBarthEet al. Monocyte subtype expression patterns in septic patients with diabetes are distinct from patterns observed in obese patients. Front Med. (2023) 9:1026298. doi: 10.3389/fmed.2022.1026298.
32
BuellGNTalabotFGosALorenzJLaiEMorrisMAet al. Gene structure and chromosomal localization of the human P2X7 receptor. Receptors channels. (1998) 5:347–54.
33
TaoJ-HChengMTangJ-PDaiX-JZhangYLiX-Pet al. Single nucleotide polymorphisms associated with P2X7R function regulate the onset of gouty arthritis. PloS One. (2017) 12:e0181685. doi: 10.1371/journal.pone.0181685
34
YangY-CChangT-YChenT-CLinW-SChangS-CLeeY-J. Functional variant of the P2X7 receptor gene is associated with human papillomavirus-16 positive cervical squamous cell carcinoma. Oncotarget. (2016) 7:82798–803. doi: 10.18632/oncotarget.v7i50.
35
CoccurelloRVolontéC. P2X7 Receptor in the management of energy homeostasis: implications for obesity, dyslipidemia, and insulin resistance. Front Endocrinol. (2020) 11:199. doi: 10.3389/fendo.2020.00199.
36
Oyanguren-DesezORodriguez-AntiguedadAVillosladaPDomercqMAlberdiEMatuteC. Gain-of-function of P2X7 receptor gene variants in multiple sclerosis. Cell Calcium. (2011) 50:468–72. doi: 10.1016/j.ceca.2011.08.002
37
AdinolfiECirilloMWoltersdorfRFalzoniSChiozziPPellegattiPet al. Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor. FASEB J. (2010) 24:3393–404. doi: 10.1096/fj.09-153601.
38
EpandRM. Proteins and cholesterol-rich domains. Biochim Biophys Acta Biomembr. (2008) 1778:1576–82. doi: 10.1016/j.bbamem.2008.03.016.
39
RobinsonLEShridarMSmithPMurrell-LagnadoRD. Plasma membrane cholesterol as a regulator of human and rodent P2X7 receptor activation and sensitization. J Biol Chem. (2014) 289:31983–94. doi: 10.1074/jbc.M114.574699
40
FengY-HWangLWangQLiXZengRGorodeskiGI. ATP stimulates GRK-3 phosphorylation and β-arrestin-2-dependent internalization of P2X7 receptor. Am J Physiol Cell Physiol. (2005) 288:C1342–56. doi: 10.1152/ajpcell.00315.2004.
41
YingYChenYLiZHuangHGongQ. Investigation into the association between P2RX7 gene polymorphisms and susceptibility to primary gout and hyperuricemia in a Chinese Han male population. Rheumatol Int. (2017) 37:571–8. doi: 10.1007/s00296-017-3669-6.
42
LiuXRaoSGongCLiTDingLWangSet al. Purinergic P2X7 receptor functional genetic polymorphisms are associated with the susceptibility to obesity in Chinese postmenopausal women. Menopause. (2018) 25:329–35. doi: 10.1097/GME.0000000000000991
43
HuntRSaunaZEAmbudkarSVGottesmanMMKimchi-SarfatyC. Silent (Synonymous) SNPs: should we care about them? In: KomarA, editor. Single Nucleotide Polymorphisms. Methods in Molecular Biology. Humana Press, Totowa, NJ (2009). p. 23–39.
44
DenlingerLCFisettePLSommerJAWattersJJPrabhuUDubyakGRet al. Cutting edge: the nucleotide receptor P2X7 contains multiple protein- and lipid-interaction motifs including a potential binding site for bacterial lipopolysaccharide. J Immunol. (2001) 167:1871–6. doi: 10.4049/jimmunol.167.4.1871
45
LeeSWLeeSOhDHParkDKimHChoiJRet al. Genetic association for P2X7R rs3751142 and CARD8 rs2043211 polymorphisms for susceptibility of gout in Korean men: multi-center study. J Korean Med Sci. (2016) 31:1566–70. doi: 10.3346/jkms.2016.31.10.1566.
46
MishraAChintagariNRGuoYWengTSuLLiuL. Purinergic P2X7 receptor regulates lung surfactant secretion in a paracrine manner. J Cell Sci. (2011) 124:657–68. doi: 10.1242/jcs.066977.
47
VereczkeiAAbdul-RahmanOHalmaiZNagyGSzekelyASomogyiAet al. Association of purinergic receptor P2RX7 gene polymorphisms with depression symptoms. Prog Neuro-Psychopharmacol Biol Psychiatry. (2019) 92:207–16. doi: 10.1016/j.pnpbp.2019.01.006.
48
YangDHeYMuñoz-PlanilloRLiuQNúñezG. Caspase-11 requires the pannexin-1 channel and the purinergic P2X7 pore to mediate pyroptosis and endotoxic shock. Immunity. (2015) 43:923–32. doi: 10.1016/j.immuni.2015.10.009
49
XuSLinYLiuWZhuXLiuDTongMet al. The P2X7 receptor mediates NLRP3-dependent IL-1β secretion and promotes phagocytosis in the macrophage response to Treponema pallidum. Int Immunopharmacol. (2020) 82:106344. doi: 10.1016/j.intimp.2020.106344.
50
GuBJSaundersBMJursikCWileyJS. The P2X7-nonmuscle myosin membrane complex regulates phagocytosis of nonopsonized particles and bacteria by a pathway attenuated by extracellular ATP. Blood J Am Soc Hematol. (2010) 115:1621–31. doi: 10.1182/blood-2009-11-251744.
51
WilhelmKGanesanJMüllerTDürrCGrimmMBeilhackAet al. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med. (2010) 16:1434–8. doi: 10.1038/nm.2242
52
PellegattiPRaffaghelloLBianchiGPiccardiFPistoiaVDi VirgilioF. Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PloS One. (2008) 3:e2599. doi: 10.1371/journal.pone.0002599
53
ParkHASeiboldPEdelmannDBennerACanzianFAlwersEet al. Validation of genetic markers associated with survival in colorectal cancer patients treated with oxaliplatin-based chemotherapy. Cancer epidemiology Biomarkers Prev. (2022) 31:352–61. doi: 10.1158/1055-9965.EPI-21-0814.
54
GTEx ConsortiumArdlieKGDelucaDSSegrèAVSullivanTJYoungTRet al. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. (2015) 348:648–60. doi: 10.1126/science.1262110
55
Martínez-GarcíaJJMartínez-BanaclochaHAngosto-BazarraDde Torre-MinguelaCBaroja-MazoAAlarcón-VilaCet al. P2X7 receptor induces mitochondrial failure in monocytes and compromises NLRP3 inflammasome activation during sepsis. Nat Commun. (2019) 10:2711. doi: 10.1038/s41467-019-10626-x
56
AlvesVSda SilvaJPRodriguesFCAraújoSMBGouvêaALLeite-AguiarRet al. P2X7 receptor contributes to long-term neuroinflammation and cognitive impairment in sepsis-surviving mice. Front Pharmacol. (2023) 14. doi: 10.3389/fphar.2023.1179723.
57
SchneiderMEVorlaenderKMaXDuWWeissM. Role of ATP in trauma-associated cytokine release and apoptosis by P2X7 ion channel stimulation. Ann New York Acad Sci. (2006) 1090:245–52. doi: 10.1196/annals.1378.027
58
IskanderKNOsuchowskiMFStearns-KurosawaDJKurosawaSStepienDValentineCet al. Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding. Physiol Rev. (2013) 93:1247–88. doi: 10.1152/physrev.00037.2012.
Summary
Keywords
P2RX7, loss-of-function (LOF), gain-of-function (GOF) single nucleotide polymorphisms (SNP), linkage disequilibrium, pneumonia, sepsis, septic shock, ATP
Citation
Guggemos J, Fuller SJ, Skarratt KK, Mayer B and Schneider EM (2024) Loss-of-function/gain-of-function polymorphisms of the ATP sensitive P2X7R influence sepsis, septic shock, pneumonia, and survival outcomes. Front. Immunol. 15:1352789. doi: 10.3389/fimmu.2024.1352789
Received
08 December 2023
Accepted
07 February 2024
Published
20 June 2024
Volume
15 - 2024
Edited by
Christoph Thiemermann, Queen Mary University of London, United Kingdom
Reviewed by
Ivana Kawikova, University of Hartford, United States
Craig Coopersmith, Emory University, United States
Updates

Check for updates
Copyright
© 2024 Guggemos, Fuller, Skarratt, Mayer and Schneider.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: E. Marion Schneider, marion.Schneider@uniklinik-ulm.de
†ORCID: E. Marion Schneider, orcid.org/0000-0003-2750-3399
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.